

## Zydus Cadila registers 30% increase in Net Profit in Q2

*Ahmedabad, 19th October 2010*

For the second quarter ended September 30, 2010, Zydus Cadila's net sales was up by 21 % y-y to Rs. 11063 mn from Rs. 9126 mn, on a consolidated basis. EBIDT was up by 19 % y-y to Rs. 2448 mn from Rs. 2057 mn. Net profit was up by 30 % to Rs. 1708 mn from Rs. 1319 mn last year.

During the quarter, the company's revenues were driven by 35% growth in the global formulations business, 19 % y-y growth in domestic formulations and 41% y-y growth in the US business. Formulations business in Brazil grew by 27%. The wellness business posted a growth of 23 %.

In the domestic formulations market, the company launched 20 new products, including line extensions, of which 10 products were the first to be launched in India.

During the quarter, Zydus Nycomed, the group's joint venture company with Nycomed, commissioned its newly expanded API manufacturing facility at Navi Mumbai. The newly commissioned facility marks the transition of Zydus Nycomed from an intermediate manufacturer to a full-fledged API manufacturer. The plant earlier provided high quality Key Starting Materials (KSMs) for manufacturing Pantoprazole. Besides other APIs, the expanded facility will now manufacture the active ingredient of Pantoprazole for Nycomed, making it one of the largest end-to-end manufacturers of this API in India.

Strengthening its regulatory pipeline, the company during the quarter, filed 2 DMFs with the USFDA, taking the cumulative filings to 93 DMFs. The company also filed 2 ANDAs and received 2 approvals, taking the cumulative number of filings to 115 and the total number of approvals to 58. Additionally, in the same period, the company filed 8 new product dossiers for the EU market, taking the cumulative filings to 98. The company has so far received 42 approvals for the EU market.

\*\*\*